Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $386.0 million.

  • Arcus Biosciences' Total Non-Current Liabilities fell 3555.93% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $386.0 million, marking a year-over-year decrease of 3555.93%. This contributed to the annual value of $508.0 million for FY2024, which is 346.23% up from last year.
  • Arcus Biosciences' Total Non-Current Liabilities amounted to $386.0 million in Q3 2025, which was down 3555.93% from $367.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Total Non-Current Liabilities high stood at $733.0 million for Q1 2022, and its period low was $260.1 million during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $503.0 million (2022), whereas its average is $490.7 million.
  • In the last 5 years, Arcus Biosciences' Total Non-Current Liabilities soared by 64608.5% in 2021 and then tumbled by 3555.93% in 2025.
  • Over the past 5 years, Arcus Biosciences' Total Non-Current Liabilities (Quarter) stood at $628.4 million in 2021, then dropped by 19.96% to $503.0 million in 2022, then fell by 2.39% to $491.0 million in 2023, then increased by 3.46% to $508.0 million in 2024, then dropped by 24.02% to $386.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $386.0 million for Q3 2025, versus $367.0 million for Q2 2025 and $459.0 million for Q1 2025.